Skip to main content
Clinical Trials/ISRCTN15363958
ISRCTN15363958
Completed
Phase 2

Multicenter, randomized, double-blind study with placebo to verify the efficacy, safety and tolerability of the modified isothymol or carvacrol compound against the SARS-CoV-2 agent in COVID-19 patients

Instituto Venezolano de Investigaciones Científicas0 sites600 target enrollmentJune 23, 2022

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
COVID-19 (SARS-CoV-2 infection)
Sponsor
Instituto Venezolano de Investigaciones Científicas
Enrollment
600
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Registry
who.int
Start Date
June 23, 2022
End Date
November 1, 2020
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Instituto Venezolano de Investigaciones Científicas

Eligibility Criteria

Inclusion Criteria

  • 1\. Positive test PDR, positive test RT\-PCR, patients diagnosed with COVID\-19
  • 2\. Chest pain or other symptom consistent with bilateral pneumonia atypical, with one of the following paraclinical alterations and imaging:
  • 3\. Oxygen saturation (SpO2\) \=93%.
  • 4\. Elevation of D\-dimer \=10 mg/mL.
  • 5\. Elevation of Ferritin \=120 ng/mL.
  • 6\. Elevation of Fibrinogen \=400 mg/dL
  • 7\. Elevation of Immunoglobulin M (IgM) \=200 mg/dL.
  • 8\. Elevation of Interleukin 6 (IL\-6\) \=1800 pg/mL.
  • 9\. Rx. chest and CT showing thickening of the bronchi, consolidation and ground glass opacities.

Exclusion Criteria

  • Negative test PDR, negative test RT\-PCR and Inadequate administration of antiviral (for non\-compliance with indicated intervals or death of the patient before 15 days treatment indications).

Outcomes

Primary Outcomes

Not specified

Similar Trials